"Consistent advantage at 2 to 5 years for post-RT ipilimumab versus placebo"
'Negative' Trial Shows OS Benefit in ... - Advanced Prostate...
'Negative' Trial Shows OS Benefit in mCRPC

Written by

snoraste
To view profiles and participate in discussions please or .
Read more about...
5 Replies
•
Not what you're looking for?
You may also like...
Urinary incontinence in mCRPC
I am looking for help for my 81-year-old father who is mCRPC. He was diagnosed at stage 4 about 18...
Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases
Combo Immune herapy showing positive signs for MCRPC. The combo of immunotherapy drugs are what...
Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show
This came out a few days ago and I don't see anyone else posted it yet. I don't subscribe to...
apalutamide shows 23% survival benefit over enzalutamide in prostate cancer study
“This real-world evidence showed a statistically significant and clinically meaningful improvement...
Zytiga vs Docetaxel in mCRPC
I just watched a video from Prostate Cancer Today which discussed the use of Docetaxel vs Zytiga in...